Last reviewed · How we verify
CICAPROST — Competitive Intelligence Brief
phase 2
cicaprost
Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype
Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
CICAPROST (CICAPROST). Cicaprost works by binding to and activating the prostacyclin receptor, mimicking the effects of prostacyclin to promote vasodilation and inhibit platelet aggregation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CICAPROST TARGET | CICAPROST | phase 2 | cicaprost | Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (cicaprost class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CICAPROST CI watch — RSS
- CICAPROST CI watch — Atom
- CICAPROST CI watch — JSON
- CICAPROST alone — RSS
- Whole cicaprost class — RSS
Cite this brief
Drug Landscape (2026). CICAPROST — Competitive Intelligence Brief. https://druglandscape.com/ci/cicaprost. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing